Class / Patent application number | Description | Number of patent applications / Date published |
424900361 | Heterocyclic compound is attached to or complexed with the metal | 47 |
20080253969 | MULTI-FUNCTIONAL POLYGLUTAMATE DRUG CARRIERS - Various biodegradable polyglutamate polymer conjugates that can include recurring units of the general formulae (I) and (II) are described herein. Such polymer conjugates are useful for variety of drug, targeting, stabilizing and/or imaging agent delivery applications. | 10-16-2008 |
20090004119 | Polymers - The present invention relates to novel linear polymers, compositions comprising said polymers and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and magnetic resonance spectroscopy (MRS). | 01-01-2009 |
20090155184 | MAGNETIC RESONANCE IMAGING METHOD - The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia. | 06-18-2009 |
20090208421 | Process for preparing a pharmaceutical formulation of contrast agents - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps:
| 08-20-2009 |
20090238768 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS - The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS). | 09-24-2009 |
20090246145 | Imaging Correlates of Neurogenesis With MRI - This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises administering to the subject a therapeutically effective amount of a compound which increases cerebral blood volume in the subject's hippocampal dentate gyrus by a percentage greater than that by which it increases the cerebral blood volume in the subject's hippocampal CA1 region, thereby treating the subject. | 10-01-2009 |
20090263332 | POLYMER PARTICLE CONTAINING PARAMAGNETIC METAL COMPOUND - A magnetic resonance imaging agent which includes: a polymer containing the structural unit represented by the following formula (I) and the structural unit represented by the following formula (II) in a molar ratio of 5 to 80:20 to 95; a paramagnetic metal compound; and a ligand molecule: | 10-22-2009 |
20100008864 | AROMATIC MULTIMERS - The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS). | 01-14-2010 |
20100098640 | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation - Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as magnetic resonance imaging (MRI). | 04-22-2010 |
20110200536 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) - The present invention relates to chelators, in particular to chelators which are capable of forming complexes, i.e. paramagnetic chelates, with paramagnetic metal ions. The invention also relates to said paramagnetic chelates, said paramagnetic chelates linked to other molecules and their use as contrast agents in magnetic resonance imaging (MRI). | 08-18-2011 |
20110243859 | ENCAPSULATING SYSTEM FOR CEST IMAGING WITH CHELATE Q GREATER THAN OR EQUAL TO 2 - The present invention relates to the use of a CEST contrast agent in a method of CEST imaging, wherein the contrast agent is a composition comprising an encapsulating system ES encapsulating at least one CEST agent, wherein the at least one CEST agent is constituted of a monomeric chelate of a chelate of q≧2 type, or of a multimer of monomeric chelates of q≧2 type, and wherein said chelate is free inside the encapsulating system. | 10-06-2011 |
20110274626 | PULSE SEQUENCING WITH HYPERPOLARISABLE NUCLEI - There is described a method of selective observation of non-hydrogenative para-hydrogen induced polarisation (NH-PHIP) as enhanced magnetic resonance signals which comprises separating the thermal and longitudinal spin order states. There is also described a template comprising [Ir(COD)(NHC)(Py)] | 11-10-2011 |
20120269738 | Imaging Beta-Amyloid Peptides and Inhibition of Beta-Amyloid Peptide Aggregation - The present invention relates to methods of detecting and monitoring aggregation of beta-amyloid peptides which are associated with neurodegenerative diseases as well as treating and/or preventing the neurodegenerative diseases by using carbazole-based fluorophores. In particular, the present invention provides methods for labeling and imaging the beta-amyloid (Aβ) peptides, oligomers, and fibrils in vitro and/or in vivo, as well as treating and/or preventing Alzheimer's disease by using the carbazole-based fluorophores of the present invention. | 10-25-2012 |
20130302257 | Compositions and Methods for Delivering Nucleic Acid Molecules and Treating Cancer - The present invention provides compositions and methods for the delivery of nucleic acids to a cell. The present invention additionally provides compositions and methods for the treatment of a disease or disorder, particularly cancer. | 11-14-2013 |
20140072517 | FE(II) SEQUESTERING AGENTS AND USES THEREOF - Compounds and uses of the compounds are provided. The compounds can be used as Fe(II) sequestering compounds. For example, these compounds can be used to sequester Fe(II) in cells, organs, vasculature, or tissues. Also, provided are compositions and methods of using the them for sequestering Fe(II) in an individual. The compounds can be used as MRI paraCEST contrast agents. | 03-13-2014 |
20150037261 | New Class Of Diazepine Derivative Chelating Agents And Complexes With Paramagnetic Metals Thereof As MRI Contrast Agents - The present invention relates to a new class of diazepine-derivatives as chelating agents for paramagnetic metal ions, the process for their preparation, and use of such paramagnetic complexes as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis. | 02-05-2015 |
20150336996 | MANGANESE-BASED MAGNETIC RESONANCE CONTRAST AGENTS - Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn | 11-26-2015 |
20160166507 | NANOEMULSIONS OF HYDROPHOBIC PLATINUM DERIVATIVES | 06-16-2016 |
424900362 | Porphyrin or derivative thereof | 4 |
20100329992 | SHIGA TOXIN B-SUBUNIT AS A VECTOR FOR TUMOR DIAGNOSIS AND DRUG DELIVERY TO GB3 EXPRESSING TUMORS - The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb | 12-30-2010 |
20110293531 | Porphyrazine Optical and Dual Optical/MR Contrast and Therapeutic Agents - Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or radiation. | 12-01-2011 |
20130202538 | Molecular Switch - Photosensitive molecular switch, having a chelate ligand, a metal ion bonded coordinatively to the chelate ligand, the metal ion being selected from the group of metal ions consisting of Mn | 08-08-2013 |
20150298115 | METHOD FOR FUNCTIONALIZING CARBON NANO-OBJECTS, COMPOSITION COMPRISING FUNCTIONALIZED CARBON NANO-OBJECTS SUSPENDED IN AN ORGANIC SOLVENT AND USES THEREOF - The invention relates to a method allowing functionalization of carbon nano-objects and in particular carbon nanotubes and graphene nanosheets, a composition comprising nano-objects functionalized by this method, suspended in an organic solvent, as well as to the uses of this composition. Suitable applications include elaboration of composite materials and, in particular, of nano-composite materials, materials intended for photovoltaics, detection devices of the detector/sensor or biodetector/biosensor type, photocatalysis systems, targeted vectorization systems for compounds of therapeutic or diagnostic interest or further contrast agents for medical imaging. | 10-22-2015 |
424900363 | Hetero ring contains at least eight members | 25 |
20080241074 | MULTI-USE MULTIMODAL IMAGING CHELATES - Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue. | 10-02-2008 |
20080305049 | Mri Contrast Agents for Diagnosis and Prognosis of Tumors - The invention relates to bifunctional conjugates comprising a receptor ligand moiety and a metal binding moiety and complexes thereof with paramagnetic lanthanide or transition metals, and to the use of the metal complexes as contrast agents in magnetic resonance imaging (MRI) of tumors and other abnormalities. | 12-11-2008 |
20100092396 | HYPERPOLARIZED 89-YTTRIUM AND METHODS RELATING THERETO - The present invention relates to the preparation of hyperpolarized | 04-15-2010 |
20100247448 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS - The present invention relates to a ligand for metals, in particular lanthanides, of the general formula (I) | 09-30-2010 |
20110038805 | COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY - The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS). | 02-17-2011 |
20110129425 | PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch1 and/or of free lanthanide C lan1; d) adjustment of C ch1 and/or of C lan1 so as to obtain C ch1=C tch1 and C lan1=0, wherein C t ch1 is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation. | 06-02-2011 |
20110165089 | Complex Compound and MRI Probe Made of Same - Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose or the like, by using the gadolinium complex compounds of the present invention as a MRI probe, the ion or compound in a living body can be detected and concentration distribution thereof may be determined. | 07-07-2011 |
20110177008 | PARAMAGNETIC METAL-NANODIAMOND CONJUGATES - The present invention provides compositions and methods for the synthesis of conjugates of paramagnetic metal ions and nanodiamonds, and uses thereof. In particular, the present invention provides synthesis of paramagnetic metal-nanodiamond conjugates and methods using such compositions as molecular imaging probes. | 07-21-2011 |
20110177009 | DRUG CARRIER PROVIDING MRI CONTRAST ENHANCEMENT - Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a | 07-21-2011 |
20110268663 | INTRAVASCULAR CONTRAST AGENTS - Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C | 11-03-2011 |
20120082624 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION OF LANTHANIDE CHELATE IN POWDER FORM - The present invention relates to a method for preparing a pharmaceutical formulation of lanthanide chelate in powder form, this powder comprising a mol/mol excess of free chelate of between 0.002 and 0.4%, said method comprising the following successive steps:
| 04-05-2012 |
20120093735 | COMPLEX COMPOUND AND MRI PROBE MADE OF SAME - Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose or the like, by using the gadolinium complex compounds of the present invention as a MRI probe, the ion or compound in a living body can be detected and concentration distribution thereof may be determined. | 04-19-2012 |
20120107248 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY - This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility. | 05-03-2012 |
20120244081 | MANGANESE CHELATES AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) - The present invention relates to manganese(II) chelates. The invention also relates to said manganese(II) chelates attached to other molecules and their use as contrast agents in magnetic resonance imaging (MRI). | 09-27-2012 |
20130011340 | COMPOSITIONS AND METHODS COMPRISING MAGNETIC RESONANCE CONTRAST AGENTS - The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging. | 01-10-2013 |
20130195768 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS - The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable steroisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable steroisomers in solution useful as concentration independent CEST responsive agents. | 08-01-2013 |
20130302258 | MRI CONTRAST AGENTS - The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene of interest) in real time in vivo, to detect changes in gene expression (of a gene of interest) over time in, for example, an individual organism, to detect gene expression changes (of a gene of interest) in response to therapeutics, in cell labeling for MR imaging, in clinical diagnostics, and in theranostics. | 11-14-2013 |
20130336898 | PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C | 12-19-2013 |
20140065075 | TARGETED CONTRAST AGENTS AND USES THEREOF - Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes an unchelated aminocarboxylate functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion is for binding to necrotic tissue in the subject. | 03-06-2014 |
20140193344 | IMAGING CONTRAST AGENTS AND USES THEREOF - Provided are macrocyclic compounds having a macrocyclic core which has at least one macrocyclic donor and at least one pendant group which has at least one donor group. The macrocyclic compounds can be complexed to Fe(II) and Ni(II). The macrocyclic compounds can be used in imaging methods. For example, the compounds can be used MRI paraCEST contrast agents. | 07-10-2014 |
20140271490 | BACTERIA-TARGETED MAGNETIC RESONANCE CONTRAST AGENTS - The present invention relates to bacteria-targeted contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to bacteria targeted MRI contrast agents that can be used to detect bacteria in vivo or in vitro. In certain embodiments, the contrast agents comprise a metal chelate conjugated to at least two Zn-dipicolylamine groups. | 09-18-2014 |
20160051706 | PROCESS FOR PRODUCING A COMPLEX OF A LANTHANIDE WITH A MACROCYCLIC LIGAND - A process for producing a complex of a lanthanide or similar compound with a macrocyclic ligand, wherein the ratio of macrocyclic ligand in free form in relation to the lanthanide or similar compound is equal or more than 0.002% mol/mol, includes the steps of a) measuring the moisture content in a sample of the macrocyclic ligand; and b) mixing an amount G of the lanthanide with an amount X3 of the macrocyclic ligand with the proviso that X3=LG+Lf+M, wherein LG is the amount of macrocyclic ligand necessary for complexing the amount G of lanthanide or similar compound, Lf is an excess amount of the macrocyclic ligand, and M is the amount of moisture present in the amount X3 of the macrocyclic ligand. | 02-25-2016 |
20160052894 | BIMODAL LIGANDS WITH MACROCYCLIC AND ACYCLIC BINDING MOIETIES, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING - Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacycicododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders. | 02-25-2016 |
20160101196 | CONTRAST MEDIUM FORMULATION AND RELATED PREPARATION METHOD - The present invention relates to a liquid pharmaceutical composition including a complex of formula (I), in which M is an ion of a paramagnetic metal and R1 to R3, X1 to X3 and K1 to K12 are such as defined in claim | 04-14-2016 |
20190142977 | GADOLINIUM-BASED CONTRAST AGENTS FOR SENSITIVE DETECTION OF Zn2+ WITH MRI | 05-16-2019 |